The FDA has approved a supplement to BLA 761202 for Byooviz (ranibizumab-nuna), the Samsung Bioepis ranibizumab biosimilar. The record in the agency's application database identifies the sponsor and the product, and marks it as a supplemental approval to an existing licence.
What a supplement is, and is not, matters here. A supplemental approval covers a change to an already-licensed product — manufacturing, labelling, presentation, or occasionally an added indication — and the database entry alone does not say which. It is not a new approval and not a new indication unless the label change says so. Anyone planning around it should read the current prescribing information rather than infer from the fact of the approval.
The context that gives it weight is cost. Ranibizumab biosimilars exist to reduce the price of anti-VEGF therapy, and in India the relevant supply is largely domestic biosimilars under CDSCO rather than the US-licensed product. An FDA action on Byooviz does not change what is available or what it costs here; it does add to the regulatory track record of the molecule, which is what supports biosimilar confidence generally.
- A supplemental approval modifies an existing licence — check the label to see what changed
- This is not a new indication unless the prescribing information says so
- The Indian anti-VEGF market runs on CDSCO-approved biosimilars, not this product
- Regulatory actions on biosimilars accumulate into the safety record clinicians rely on
- Do not quote an approval date as evidence of a clinical change
Why it matters
Biosimilar licence actions are often reported as though they were new evidence; this one is a record of a supplement.
Don't overread it
A licence supplement is not a new indication and carries no new efficacy or safety finding in itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free